VIR Stock Analysis: Vir Biotechnology | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.693m USD | 12M Return: 94.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 17.9M
Qual. Beats: -1
Rev. Trend: -68.2%
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 6.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Vir Biotechnology is a clinical-stage biopharmaceutical company developing therapeutics for serious infectious diseases and cancer. Its pipeline targets hepatitis delta virus (HDV) and solid tumors, with preclinical work on influenza A/B antibodies, antibody drug conjugates, coronavirus monoclonal antibodies, and PRO-XTEN dual-masked T-cell engagers. The company maintains a partnership-heavy business model, with collaboration and license agreements with entities including Alnylam Pharmaceuticals, GlaxoSmithKline Biologicals, the Gates Foundation, and Xencor, among others. As a clinical-stage biotech with no marketed products yet, Vir relies on these partnerships and grant funding to support R&D. Incorporated in 2016 and headquartered in San Francisco, Vir trades on NASDAQ under the ticker VIR and is classified within the Health Care / Biotechnology sub-industry.
- HDV therapy clinical trial readouts near-term stock catalysts
- GSK and Alnylam collaboration milestones offset cash burn
- PRO-XTEN solid tumor platform expands oncology pipeline valuation
- COVID antibody program faces uncertain commercial demand
| Net Income: -442.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.36 > 0.02 and ΔFCF/TA 2.02 > 1.0 |
| NWC/Revenue: 686.2% < 20% (prev 3.81k%; Δ -3.12k% < -1%) |
| CFO/TA -0.43 > 3% & CFO -446.1m > Net Income -442.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (147.4m) vs 12m ago 7.19% < -2% |
| Gross Margin: 82.13% > 18% (prev -2.33k%; Δ 2.41k% > 0.5%) |
| Asset Turnover: 5.61% > 50% (prev 1.60%; Δ 4.02% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.44 (Total Current Assets 523.0m - Total Current Liabilities 73.6m) / Total Assets 1.03b |
| B: -1.29 (Retained Earnings -1.32b / Total Assets 1.03b) |
| C: -0.39 (EBIT TTM -450.1m / Avg Total Assets 1.17b) |
| D: 3.82 (Book Value of Equity 812.8m / Total Liabilities 212.8m) |
| Altman-Z'' = 0.08 = B |
As of July 08, 2026, the stock is trading at USD 10.25 with a total of 1,352,009 shares traded. Over the past week, the price has changed by -1.25%, over one month by +21.30%, over three months by +11.78% and over the past year by +94.50%.
Current recommended Stop Loss: 9.60 (which is 6.3% or 1.3 ATR below the current price).
Vir Biotechnology has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy VIR.
- StrongBuy: 2
- Buy: 5
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21.6 | 110.3% |
P/E Forward = 4.2717
P/S = 25.8534
P/B = 1.9837
Revenue TTM = 65.5m USD
EBIT TTM = -450.1m USD
EBITDA TTM = -438.5m USD
Long Term Debt = 86.6m USD (estimated: total debt 95.6m - short term 8.94m)
Short Term Debt = 8.94m USD (from shortTermDebt, last quarter)
Debt = 95.6m USD (from shortLongTermDebtTotal, last quarter) (leases 95.6m already included)
Net Debt = -376.8m USD (calculated: Debt 95.6m - CCE 472.4m)
Enterprise Value = 1.32b USD (1.69b + Debt 95.6m - CCE 472.4m)
Interest Coverage Ratio = unknown (Ebit TTM -450.1m / Interest Expense TTM 0.0)
EV/FCF = -3.52x (Enterprise Value 1.32b / FCF TTM -373.8m)
FCF Yield = -28.39% (FCF TTM -373.8m / Enterprise Value 1.32b)
FCF Margin = -570.7% (FCF TTM -373.8m / Revenue TTM 65.5m)
Net Margin = -676.0% (Net Income TTM -442.7m / Revenue TTM 65.5m)
Gross Margin = 82.13% ((Revenue TTM 65.5m - Cost of Revenue TTM 11.7m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.28 (Enterprise Value 1.32b / Total Assets 1.03b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 95.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -355.6m (EBIT -450.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.62 (Total Current Assets 523.0m / Total Current Liabilities 79.0m)
Debt / Equity = 0.12 (Debt 95.6m / totalStockholderEquity, last quarter 812.8m)
Debt / EBITDA = 0.86 (negative EBITDA) (Net Debt -376.8m / EBITDA -438.5m)
Debt / FCF = 1.01 (negative FCF - burning cash) (Net Debt -376.8m / FCF TTM -373.8m)
Total Stockholder Equity = 830.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.95% (Net Income -442.7m / Total Assets 1.03b)
RoE = -53.31% (Net Income TTM -442.7m / Total Stockholder Equity 830.4m)
RoCE = -49.09% (EBIT -450.1m / Capital Employed (Equity 830.4m + L.T.Debt 86.6m))
RoIC = -37.13% (negative operating profit) (NOPAT -355.6m / Invested Capital 957.7m)
WACC = 11.23% (E(1.69b)/V(1.79b) * Re(11.86%) + D(95.6m)/V(1.79b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 4.10%
[DCF] Fair Price = unknown (Cash Flow -373.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -3.79 | # QB: -1
Revenue Correlation: -68.22 | Revenue CAGR: -50.12% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.90 | Chg30d=+0.00% | Revisions=+0% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.81 | Chg30d=-1.51% | Revisions=+40% | Analysts=5
EPS current Year (2026-12-31): EPS=-1.37 | Chg30d=-1.63% | Revisions=+0% | GrowthEPS=+56.5% | GrowthRev=+263.8%
EPS next Year (2027-12-31): EPS=-2.32 | Chg30d=-1.09% | Revisions=+0% | GrowthEPS=-69.2% | GrowthRev=-54.7%
[Analyst] Revisions Ratio: +15% (up=6, down=4)